Compare · HIMS vs TOI
HIMS vs TOI
Side-by-side comparison of Hims & Hers Health Inc. (HIMS) and The Oncology Institute Inc. (TOI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HIMS and TOI operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- HIMS is the larger of the two at $7.60B, about 14.2x TOI ($534.9M).
- Over the past year, HIMS is down 34.8% and TOI is up 53.0% - TOI leads by 87.8 points.
- TOI has been more active in the news (8 items in the past 4 weeks vs 7 for HIMS).
- HIMS has more recent analyst coverage (25 ratings vs 8 for TOI).
- Company
- Hims & Hers Health Inc.
- The Oncology Institute Inc.
- Price
- $32.86-2.41%
- $5.36+1.81%
- Market cap
- $7.60B
- $534.9M
- 1M return
- +4.42%
- +4.79%
- 1Y return
- -34.76%
- +53.00%
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 7
- 8
- Recent ratings
- 25
- 8
Hims & Hers Health Inc.
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, collagen protein, biotin, and teas in the wellness category; moisturizer, fragrances, face wash, and anti-wrinkle creams in the skincare category; condoms and lubricants in the sexual health category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. It also offers medical consultation services; and engages in the wholesale of non-prescription product sales to retailers. Hims & Hers Health, Inc. is based in San Francisco, California.
The Oncology Institute Inc.
The Oncology Institute, Inc. provides cancer awareness, prevention, diagnosis, treatment, and education service. The company offers chemotherapy education, comprehensive lab testing, pain management, financial counseling, end of life counseling, dietary counseling, in-house infusion center, in-house support groups, in-house pharmacy, nutraceuticals, clinical trials, and educational seminars. It also operates the hope, health, and healing center to offer patients alternative and holistic treatments in addition to chemotherapy. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Latest HIMS
- Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company
- Hims & Hers Health Inc. filed SEC Form 8-K: Leadership Update
- Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026
- Chief Financial Officer Okupe Oluyemi exercised 7,163 shares at a strike of $5.01 and sold $261,351 worth of shares (7,163 units at $36.49) as part of a pre-agreed trading plan (SEC Form 4)
- Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Chief Medical Officer Carroll Patrick Harrison sold $830,410 worth of shares (23,726 units at $35.00), decreasing direct ownership by 12% to 181,861 units (SEC Form 4)
- Chief Financial Officer Okupe Oluyemi exercised 6,376 shares at a strike of $5.01 and sold $619,217 worth of shares (18,197 units at $34.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 284,321 units (SEC Form 4)
- Chief Financial Officer Okupe Oluyemi converted options into 71,616 shares and covered exercise/tax liability with 39,541 shares, increasing direct ownership by 12% to 296,142 units (SEC Form 4) to cover withholding tax
- Chief Medical Officer Carroll Patrick Harrison converted options into 25,926 shares and covered exercise/tax liability with 8,310 shares, increasing direct ownership by 9% to 205,587 units (SEC Form 4) (withholding tax)
- Chief Operating Officer Chi Michael covered exercise/tax liability with 47,699 shares, sold $441,850 worth of shares (14,027 units at $31.50) as part of a pre-agreed trading plan and converted options into 86,264 shares, increasing direct ownership by 6% to 432,124 units (SEC Form 4) (withholding obligation)
Latest TOI
- Chief Medical Officer Podnos Yale exercised 23,452 shares at a strike of $1.90 and sold $150,340 worth of shares (23,452 units at $6.41) (SEC Form 4)
- Large owner Chernett Jorey bought $87,750 worth of shares (15,000 units at $5.85), increasing direct ownership by 0.14% to 10,630,858 units (SEC Form 4)
- Director Tzoumakas Kimberly Jo was granted 17,185 shares (SEC Form 4)
- Director Stolper Mark was granted 25,833 shares (SEC Form 4)
- The Oncology Institute Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity
- Lake Street initiated coverage on The Oncology Institute with a new price target
- Large owner Chernett Jorey bought $90,360 worth of shares (18,000 units at $5.02), increasing direct ownership by 0.17% to 10,615,858 units (SEC Form 4)
- The Oncology Institute Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Medical Officer Podnos Yale sold $126,094 worth of shares (23,451 units at $5.38) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 259,527 units (SEC Form 4)